JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Scientists have long considered ketones (a fundamental chemical class) and esters (molecules formed when an acid reacts with ...

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes and sells ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by 2025, reflecting ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...

The stock's fall snapped a two-day winning streak.

The UK's self-regulated system for disclosing payments from drug companies to health care professionals and organizations is ...